Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Unlock Full ARKG Analysis
UpgradeKey Numbers
Market Cap
$2B
P/E
N/A
Revenue Growth
0.0%
Gross Margin
N/A
ROE
N/A
About ARK Genomic Revolution ETF
Listed on the CBOE, ARK Genomic Revolution ETF operates as a small-cap player in the biotech sector, participating in the biotech and genomics opportunity as part of a broader strategy. ETF focused on companies advancing genomics, gene editing, and therapeutics. With a $2B market capitalization and no current profitability, the business is characterized by top-line contraction, reporting 0% revenue change year-over-year.
Expert Coverage
Loading coverage...
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-03-22
More in Biotech & Genomics
DXCM
DexCom Inc.
85
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55ALNY
Alnylam Pharmaceuticals
85
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%LLY
Eli Lilly and Company
85
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65BEAM
Beam Therapeutics
84
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3B